Literature DB >> 16639430

Microbicides and other topical strategies to prevent vaginal transmission of HIV.

Michael M Lederman1, Robin E Offord, Oliver Hartley.   

Abstract

The HIV epidemic is, by many criteria, the worst outbreak of infectious disease in history. The rate of new infections is now approximately 5 million per year, mainly in the developing world, and is increasing. Women are now substantially more at risk of infection with HIV than men. With no cure or effective vaccine in sight, a huge effort is required to develop topical agents (often called microbicides) that, applied to the vaginal mucosa, would prevent infection of these high-risk individuals. We discuss the targets for topical agents that have been identified by studies of the biology of HIV infection and provide an overview of the progress towards the development of a usable agent.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16639430     DOI: 10.1038/nri1848

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  72 in total

1.  In vitro activities of candidate microbicides against cell-associated HIV.

Authors:  Philippe Selhorst; Katrijn Grupping; Thomas Bourlet; Olivier Delézay; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

2.  Anti-HIV-1 efficacy of extracts from medicinal plants.

Authors:  Su-A Lee; Seong-Karp Hong; Chang-Il Suh; Mi-Hwa Oh; Jeong-Ho Park; Byoung-Wook Choi; Seung-Won Park; Soon-Young Paik
Journal:  J Microbiol       Date:  2010-05-01       Impact factor: 3.422

3.  The microbicide tenofovir does not inhibit nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine samples.

Authors:  Billie Jo Wood; Patricia Rizzo-Price; Jeff Holden; Andrew Hardick; Thomas C Quinn; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

4.  Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.

Authors:  Ronald S Veazey; Thomas A Ketas; Per Johan Klasse; Donna K Davison; Morgan Singletary; Linda C Green; Michael L Greenberg; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-22       Impact factor: 11.205

5.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.

Authors:  Paolo Ingallinella; Elisabetta Bianchi; Neal A Ladwa; Ying-Jie Wang; Renee Hrin; Maria Veneziano; Fabio Bonelli; Thomas J Ketas; John P Moore; Michael D Miller; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

6.  Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.

Authors:  Hubert Gaertner; Fabrice Cerini; Jean-Michel Escola; Gabriel Kuenzi; Astrid Melotti; Robin Offord; Irène Rossitto-Borlat; Rebecca Nedellec; Janelle Salkowitz; Guy Gorochov; Donald Mosier; Oliver Hartley
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-12       Impact factor: 11.205

7.  EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.

Authors:  Takamitsu Matsuzawa; Tatsuyoshi Kawamura; Youichi Ogawa; Kenji Maeda; Hirotomo Nakata; Kohji Moriishi; Yoshio Koyanagi; Hiroyuki Gatanaga; Shinji Shimada; Hiroaki Mitsuya
Journal:  J Invest Dermatol       Date:  2013-11-11       Impact factor: 8.551

8.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

9.  Differences in immunoregulatory cytokine expression patterns in the systemic and genital tract compartments of HIV-1-infected commercial sex workers in Benin.

Authors:  J Lajoie; J Poudrier; M Massinga-Loembe; F Guédou; C Agossa-Gbenafa; A-C Labbé; M Alary; M Roger
Journal:  Mucosal Immunol       Date:  2008-05-14       Impact factor: 7.313

Review 10.  Novel humanized murine models for HIV research.

Authors:  Paul W Denton; J Victor Garcia
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.